Andoh Kiyohiko, Suenaga Kiyotaka, Sakaguchi Masashi, Yamazaki Kenichi, Honda Takashi
Animal Pharmaceuticals Division, The Chemo-Sero-Therapeutic Research Institute, 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto 860-8568, Japan.
R&D Division, The Chemo-Sero-Therapeutic Research Institute, Kikuchi Research Center, 1314-1 Kyokushikawabe, Kikuchi-shi, Kumamoto 869-1298, Japan.
Virus Res. 2015 Oct 2;208:164-70. doi: 10.1016/j.virusres.2015.06.019. Epub 2015 Jun 22.
We evaluated the antigenicity of recombinant infectious bronchitis virus (IBV) S1 protein expressed in mammalian cells. Recombinant S1 was expressed as a secreted protein fused with a trimerization motif peptide, then purified using Ni Sepharose. The purified protein was analyzed by Western blotting, mixed with oil adjuvant, and administered to 29-day-old specific-pathogen-free chickens. Six weeks after immunization, anti-IBV neutralizing titer and anti-S1 ELISA titer were determined; immunized chickens then were inoculated with IBV via the trachea and ciliary activity was observed. Results showed that the recombinant S1 protein was highly glycosylated, and the neutralizing antigenicity of recombinant S1 protein was lower than that of inactivated virus. However, anti-S1 ELISA indicated that the recombinant S1 protein induced antibodies against S1. These results suggest that the recombinant S1 may retain non-neutralizing epitopes but have unnatural glycosylation pattern and conformation, resulting in lacking neutralizing conformational epitopes. In conclusion, the neutralizing antigenicity of recombinant S1 protein expressed from mammalian cells was decreased, and was not sufficient to induce neutralizing antibodies.
我们评估了在哺乳动物细胞中表达的重组传染性支气管炎病毒(IBV)S1蛋白的抗原性。重组S1蛋白作为与三聚化基序肽融合的分泌蛋白表达,然后使用镍琼脂糖凝胶进行纯化。通过蛋白质免疫印迹法分析纯化后的蛋白,将其与油佐剂混合,并接种于29日龄的无特定病原体鸡。免疫六周后,测定抗IBV中和效价和抗S1酶联免疫吸附测定(ELISA)效价;然后经气管给免疫鸡接种IBV,并观察纤毛活性。结果显示,重组S1蛋白高度糖基化,且重组S1蛋白的中和抗原性低于灭活病毒。然而,抗S1 ELISA表明重组S1蛋白诱导产生了针对S1的抗体。这些结果表明,重组S1可能保留了非中和表位,但具有不自然的糖基化模式和构象,导致缺乏中和性构象表位。总之,从哺乳动物细胞表达的重组S1蛋白的中和抗原性降低,不足以诱导产生中和抗体。